Fig. 1

A/B. Schematic presentation of the model structure. (A) Patients spent each annual cycle in one of the health states: Oval represents health states while the arrows imply possible transitions of patients among different health states. (B) Illustrative model structure of the CASPO->L-AmB treatment strategy for IC/C patients. During each cycle, patients treated with any of the antifungal drugs could experience treatment success or failure. Those who had failed the first-line therapy could die due to the infection or survive and later would be switched to the next alternative therapy. Patients were also at risk of death due to causes unrelated to the infection. CASPO: Caspofungin; L-AmB: Liposomal amphotericin B